Boston Scientific Corporation $BSX Holdings Trimmed by Zions Bancorporation National Association UT

Zions Bancorporation National Association UT reduced its position in shares of Boston Scientific Corporation (NYSE:BSX) by 35.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,072 shares of the medical equipment provider’s stock after selling 1,714 shares during the period. Zions Bancorporation National Association UT’s holdings in Boston Scientific were worth $330,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC raised its holdings in shares of Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider’s stock worth $2,445,000 after purchasing an additional 226 shares in the last quarter. Westmount Partners LLC bought a new position in shares of Boston Scientific in the first quarter valued at $263,000. Pittenger & Anderson Inc. boosted its stake in shares of Boston Scientific by 26.8% during the 1st quarter. Pittenger & Anderson Inc. now owns 6,342 shares of the medical equipment provider’s stock worth $640,000 after acquiring an additional 1,342 shares in the last quarter. CWM LLC grew its holdings in shares of Boston Scientific by 8.2% in the 1st quarter. CWM LLC now owns 37,476 shares of the medical equipment provider’s stock worth $3,781,000 after acquiring an additional 2,844 shares during the last quarter. Finally, LRI Investments LLC raised its position in shares of Boston Scientific by 9.4% during the first quarter. LRI Investments LLC now owns 6,403 shares of the medical equipment provider’s stock worth $646,000 after purchasing an additional 551 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Stock Performance

Shares of BSX opened at $100.94 on Tuesday. The company has a market capitalization of $149.64 billion, a PE ratio of 53.98, a PEG ratio of 2.02 and a beta of 0.58. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company’s 50 day moving average price is $100.00 and its 200 day moving average price is $102.52. Boston Scientific Corporation has a 52 week low of $85.98 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. Boston Scientific had a net margin of 14.43% and a return on equity of 19.74%. The company had revenue of $5.07 billion during the quarter, compared to the consensus estimate of $4.97 billion. During the same quarter in the prior year, the firm earned $0.63 EPS. The company’s revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on BSX. Evercore ISI restated an “outperform” rating on shares of Boston Scientific in a report on Wednesday, October 22nd. Needham & Company LLC reissued a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a research report on Friday, October 17th. Barclays upped their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a research report on Thursday, October 2nd. Leerink Partners lifted their price objective on shares of Boston Scientific from $127.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Finally, Oppenheimer raised shares of Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $118.00 to $125.00 in a research note on Monday, September 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of “Buy” and an average price target of $123.77.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $99.47, for a total value of $4,973,500.00. Following the completion of the sale, the executive vice president owned 178,342 shares of the company’s stock, valued at approximately $17,739,678.74. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Ellen M. Zane sold 12,891 shares of the firm’s stock in a transaction that occurred on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. The trade was a 34.82% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 175,782 shares of company stock valued at $17,742,314. Insiders own 0.50% of the company’s stock.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.